Cancer clinical trials in the region Centre-Val de Loire
118 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Multiple myeloma
#NCT05519085
#2023-509859-13-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
Celgene
Phase 3
Multiple myeloma
#NCT06918002
#2024-516418-39-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
56 recruiting sites
Intergroupe Francophone du Myélome
Phase 3
Multiple myeloma
#NCT06152575
#2023-507871-23-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
13 recruiting sites
Pfizer
Phase 3
Amyloidosis
#NCT07052903
#2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
15 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
15 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Breast cancer
#NCT05512364
#2022-501453-36-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Surgery
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06456346
#2023-505232-36-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Essential thrombocythemia
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Cytoreductive therapy
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05198960
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera
Essential thrombocythemia
Primary myelofibrosis
Required genetic anomalies
JAK2
19 recruiting sites
Hôpital Universitaire de Brest